FDA Grants Accelerated Approval to the Combination of Avutometinib and Defactinib for Select Patients With Ovarian Cancer

On May 8, the US Food and Drug Administration (FDA) granted accelerated approval to the combination of avutometinib and defactinib for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy.

For more information, read the FDA announcement and the Verastem press release.

Posted on 5/19/2025